Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Europe's drug committee has recommended approving relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer — a notoriously difficult-to-treat condition. Data from the phase 3 ROSELLA trial showed the combo extended median overall survival by over 4 months compared to nab-paclitaxel alone. A final European Commission decision is expected later in 2026.
Europe's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of relacorilant (Lifyorli) combined with nab-paclitaxel (Abraxane) for adult patients with platinum-resistant ovarian cancer — a setting where treatment options remain limited and prognosis is poor. The European Commission is expected to issue a final marketing authorization decision later in 2026.
The recommendation is backed by results from the phase 3 ROSELLA trial, which enrolled 381 patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer who had progressed within 6 months of platinum-based therapy. Patients received either the relacorilant combination or nab-paclitaxel monotherapy. The OS benefit was consistent across subgroups, including those with a short taxane-free interval.
By the Numbers:
Why it matters: Platinum-resistant ovarian cancer has very few effective treatment options, making this combination — which targets the glucocorticoid receptor — a meaningful potential addition to the European oncology toolkit.
